César Alejandro
Soutullo Esperón
Investigador ata 2019
![Foto de César Alejandro](/img/nophoto.png)
![Foto de Eli Lilly and Company](/img/noimage_org.png)
Eli Lilly and Company
Indianapolis, EE. UU.Publicacións en colaboración con investigadores/as de Eli Lilly and Company (7)
2015
-
Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder
European Neuropsychopharmacology, Vol. 25, Núm. 10, pp. 1611-1621
2013
-
Evaluating Internet information on attention-deficit/hyperactivity disorder (ADHD) treatment: parent and expert perspectives.
Education for health (Abingdon, England), Vol. 26, Núm. 1, pp. 48-53
-
Evaluating internet information on attention- deficit/hyperactivity disorder (ADHD) treatment: Parent and expert perspectives
Education for Health: Change in Learning and Practice, Vol. 26, Núm. 1, pp. 48-53
2008
-
Attention deficit/hyperactivity disorder: Burden of the disease according to subtypes in recently diagnosed children
Actas Espanolas de Psiquiatria, Vol. 36, Núm. 5, pp. 285-294
2005
-
Seguridad y eficacia de la atomoxetina en niños con trastorno por déficit de atención/hiperactividad (TDAH): Fase inicial durante 10 semanas en estudio de prevención de recaídas en una muestra española
Actas Espanolas de Psiquiatria, Vol. 33, Núm. 1, pp. 26-32
-
Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children
Pediatrics, Vol. 116, Núm. 3
2004
-
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD
European Child and Adolescent Psychiatry, Vol. 13, Núm. 4, pp. 249-257